Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

NCT03604159
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 28, 2026, 6:28 AM EDT
Recruiting Not applicable Interventional

NavSTAR Implementation Effectiveness Trial Across a Health System

NCT07262190
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NavSTAR (Philly adaptation)
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

NCT05704543
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine Extended-Release Injection
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
San Diego, California • Hollywood, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Providing Suboxone and PrEP Using Telemedicine

NCT04521920
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions
Suboxone, PrEP
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 28, 2026, 6:28 AM EDT
Completed No phase listed Observational

Fetal Neurobehavior in Poly-drug Dependent Women

NCT00653692
View directory record Official record
Conditions
Poly Drug Exposed Pregnancies
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients

NCT00295308
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Clonidine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 28, 2026, 6:28 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

NCT05944952
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Shoulder Arthroplasty

NCT01782872
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Interscalene Block (ISB) - 0.375% Ropivacaine + additives, Interscalene Block (ISB) - 0.2% Ropivacaine + additives, Interscalene Block (ISB) - 0.1% Ropivacaine + additives, Interscalene Block (ISB) - Systemic Control
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 1Phase 2 Interventional

Yoga for Pain and Opioid Dependence

NCT01590251
View directory record Official record
Conditions
Chronic Pain, Opioid Addiction
Interventions
Yoga, Educational Counseling
Other · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 28, 2026, 6:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail

NCT06593353
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorders
Interventions
Systems Analysis and Improvement Approach (SAIA)
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 110 Years
Enrollment
4,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 6:28 AM EDT
Completed No phase listed Observational

Using mHealth to Aid Opioid Addicts

NCT01955902
View directory record Official record
Conditions
Opiate Dependency Relapse
Interventions
Not listed
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

NCT02413281
View directory record Official record
Conditions
Healthy
Interventions
ALKS 5461, Buprenorphine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Opiate Suicide Study in Patients With Major Depression

NCT04116528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

NCT00000302
View directory record Official record
Conditions
Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 28, 2026, 6:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement

NCT05897788
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence With Current Use (Disorder)
Interventions
Text Message Check-ins, Contingency Management
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270
View directory record Official record
Conditions
Opioid Dependence
Interventions
Isradipine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 28, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Treatment Efficacy for Drug Abuse and AIDS Prevention - 1

NCT00000210
View directory record Official record
Conditions
Cocaine-Related Disorders, Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
26 Years to 41 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1996
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 28, 2026, 6:28 AM EDT
Recruiting Not applicable Interventional

Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder

NCT07079826
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Use Disorder (OUD)
Interventions
Sparrow Link (Active tAN), Sparrow Link (Sham tAN)
Device
Lead sponsor
Payel Roy
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 28, 2026, 6:28 AM EDT
Completed No phase listed Observational

Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder

NCT03544112
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Employ a multifaceted approach to facilitate clinical protocol implementation, Initiate BUP (SL-BUP or XR-BUP) in the ED
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Claremont, New Hampshire • Manchester, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 28, 2026, 6:28 AM EDT
Withdrawn Phase 3 Interventional

Anti-suicidal Effects of Buprenorphine In Depressed Individuals

NCT05427981
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
Belbuca Buccal Product, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 28, 2026, 6:28 AM EDT